Thalidomide, drug safety and early drug regulation in the UK

Adverse Drug Reactions and Toxicological Reviews

Volumn 20, Issue 4, 2001, Pages 199-255

  Shah, R R ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Clinical trials exemption; Committee on Safety of Drugs; Committee on Safety of Medicines; Committee on the Review of Medicines; Drug regulation; Licensing Authority; Medicines Commission; Product licenses of right; Yellow card scheme

Indexed keywords

ADRENALIN; ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTIRHEUMATIC AGENT; ARSPHENAMINE; BARBITURIC ACID DERIVATIVE; BENZIODARONE; CHLORAMPHENICOL; CHLOROFORM; ESTROGEN; HYPNOTIC SEDATIVE AGENT; IBUFENAC; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; LEVODOPA; MEFENAMIC ACID; MONOAMINE OXIDASE INHIBITOR; NITRAZEPAM; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; ORAL CONTRACEPTIVE AGENT; OXYPHENBUTAZONE; PHENYLBUTAZONE; PRONETALOL; PSYCHOTROPIC AGENT; SEQUENTIAL CONTRACEPTIVE AGENT; THALIDOMIDE; UNINDEXED DRUG; VACCINE; VASODILATOR AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADDICTION; BEHCET DISEASE; CLINICAL TRIAL; DEPRESSION; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG FATALITY; DRUG LABELING; DRUG LEGISLATION; DRUG MARKETING; DRUG POTENTIATION; DRUG QUALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HANGOVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; JAUNDICE; LEPROSY; LICENSING; LIVER INJURY; LIVER NECROSIS; MYELOMA; NEUROPATHY; NONHUMAN; PARKINSONISM; PERIPHERAL VASCULAR DISEASE; PHOCOMELIA; PRACTICE GUIDELINE; REVIEW; STANDARDIZATION; TERATOGENICITY; TOXICITY TESTING; UNITED KINGDOM; VOMITING;

ABNORMALITIES, DRUG-INDUCED; GREAT BRITAIN; HISTORY, 20TH CENTURY; HUMANS; LEGISLATION, DRUG; STATE MEDICINE; TERATOGENS; THALIDOMIDE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0035199410     PISSN: 0964198X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. `Stalinon': A therapeutic disaster
2. Iatrogenic disease: An historical survey of adverse reactions before thalidomide. Chapter 2
3. Stereochemical origin of some clinically significant drug safety concerns: Lessons for future drug development
4. Drug-induced hepatotoxicity: Pharmacokinetic perspectives and strategies for risk reduction
5. Elixirs, diluents and the passage of the 1938 Federal Food, Drug and Cosmetic Act
6. The history of the United States Food, Drug and Cosmetic Act and the development of medicine
7. The pharmacologic evaluation of new drugs
8. A survey of products licensed in the United Kingdom from 1971-1981
9. New active substances authorized in the United Kingdom between 1972 and 1994
10. The review of medicines in the United Kingdom
11. New procedures affecting the conduct of clinical trials in the United Kingdom
12. A survey of the first year of operation of the new procedure affecting the conduct of clinical trials in the United Kingdom
13. The United Kingdom Clinical Trial Exemption Scheme - Its effects on investment in research
14. Roussel convicted of misleading promotion
15. Thalidomide in the management of multiple myeloma
16. Thalidomide and dexamethasone combination for refractory multiple myeloma
17. The re-emergence of thalidomide: Results of a scientific conference
18. Guidance on thalidomide. Committee on Safety of Medicines/Medicines Control Agency, London
19. Guideline for the clinical use and dispensing of thalidomide
20. Thalidomide: 35 years on and still deforming
21. Brazil investigates drug's possible link with birth defects
22. The return of thalidomide: Can birth defects be prevented